

## Sepsis: new definitions - novel treatments

Prof. Zsolt Molnár

zsoltmolna@gmail.com

Department of Anaesthesia and Intensive Therapy

University of Szeged, Hungary



Hungary



New definitions: "Sepsis-3"



### The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Mervyn Singer, MD, FRCP; Clifford S. Deutschman, MD, MS; Christopher Warren Seymour.

Djillali Annane, MD, PhD; Michael Bauer, MD; Rinaldo Bellomo, MD; Gordon R. Bernard, MD,
Craig M. Coopersmith, MD; Richard S. Hotchkiss, MD; Mitchell M. Levy, MD; John C. Marshall,
Steven M. Opal, MD; Gordon D. Rubenfeld, MD, MS; Tom van der Poll, MD, PhD; Jean-Louis Vin

MSc; Manu Shankar-Hari, MSc, MD, FFICM; Daniel Chiche, MD, PhD; g S. Martin, MD, MSc;

PhD; Derek C. Angus, MD, MPH

Q doi:10,1001/jama,2016,0287



Developing a New Definition and Assessing New Clinical Criteria for Septic Shock

For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Manu Shankar-Hari, MD, MSc; Gary S. Phillips, MAS; Mitchell L. Levy, MD; Christopher W. Seymour, MD, MSc; Vincent X. Liu, MD, Clifford S. Deutschman, MD; Derek C. Angus, MD, MPh; Gordon D. Rubenfeld, MD, MSc; Mervyn Singer, MD, FRCP; for the Sepsis De

1,020,681 8 Views Citations

### Application of a Framework to Assess the Usefulness of Alternative Sepsis Criteria

Christopher W. Seymour, MD<sup>1</sup>; Craig M. Coopersmith, MD<sup>2</sup>; Clifford S. Deutschman, MD<sup>3</sup>; Foster Gesten, MD<sup>4</sup>; Michael Klompas, MD<sup>5</sup>; Mitchell Levy, MD<sup>6</sup>; Gregory S. Martin, MD<sup>7</sup>; Tiffany M. Osbara, MD<sup>8</sup>, Chang Phoe, MD<sup>5</sup>, David K. Warran, MD<sup>9</sup>, P. Scott Watson, MD<sup>10</sup>.

Derek C. Ang

### A Framework for the Development and Interpretation of Different Sepsis Definitions and Clinical Criteria

Derek C. Angus, MD<sup>1</sup>; Christopher W. Seymour, MD<sup>1</sup>; Craig M. Coopersmith, MD<sup>2</sup>; Clifford S. Deutschman, MD<sup>3</sup>; Michael Klompas, MD<sup>4,5</sup>; Mitchell M. Levy, MD<sup>6</sup>; Gregory S. Martin, MD<sup>7</sup>; Tiffany M. Osborn, MD<sup>8</sup>; Chanu Rhee, MD<sup>4,5</sup>; R. Scott Watson, MD<sup>9</sup>

(Crit Care Med 2016; 44:e113-e121)





### The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Mervyn Singer, MD, FRCP; Clifford S. Deutschman, MD, MS; Christopher Warren Seymour, MD, MSc; Manu Shankar-Hari, MSc, MD, FFICM; Djillali Annane, MD, PhD; Michael Bauer, MD; Rinaldo Bellomo, MD; Gordon R. Bernard, MD; Jean-Daniel Chiche, MD, PhD; Craig M. Coopersmith, MD; Richard S. Hotchkiss, MD; Mitchell M. Levy, MD; John C. Marshall, MD; Greg S. Martin, MD, MSc; Steven M. Opal, MD; Gordon D. Rubenfeld, MD, MS; Tom van der Poll, MD, PhD; Jean-Louis Vincent, MD, PhD; Derek C. Angus, MD, MPH

JAMA. 2016;315(8):801-810. doi:10.1001/jama.2016.0287

### A Need for Sepsis Definitions for the Public and for Health Care Practitioners

Despite its worldwide importance, <sup>6,7</sup> public awareness of sepsis is poor. <sup>29</sup> Furthermore, the various manifestations of sepsis make diagnosis difficult, even for experienced clinicians. Thus, the public needs an understandable definition of sepsis, whereas health care practitioners require improved clinical prompts and diagnostic approaches to facilitate earlier identification and an accurate quantification of the burden of sepsis.



### The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)



Mervyn Singer, MD, FRCP; Clifford S. Deutschman, MD, MS; Christopher Warren Seymour, MD, MSc; Manu Shankar-Hari, MSc, MD, FFICM; Djillali Annane, MD, PhD; Michael Bauer, MD; Rinaldo Bellomo, MD; Gordon R. Bernard, MD; Jean-Daniel Chiche, MD, PhD; Craig M. Coopersmith, MD; Richard S. Hotchkiss, MD; Mitchell M. Levy, MD; John C. Marshall, MD; Greg S. Martin, MD, MSc; Steven M. Opal, MD; Gordon D. Rubenfeld, MD, MS; Tom van der Poll, MD, PhD; Jean-Louis Vincent, MD, PhD; Derek C. Angus, MD, MPH

JAMA. 2016;315(8):801-810. doi:10.1001/jama.2016.0287

Full details are found in the accompanying article by Seymour et al. <sup>12</sup> In brief, electronic health record data of 1.3 million encounters at 12 community and academic hospitals within the University of Pittsburgh Medical Center health system in southwestern Pennsylvania were studied. There were 148 907 patients with suspected infection, identified as those who had body fluids sampled for culture and received antibiotics. Two outcomes—hospital mortality and mortality, ICU stay of 3 days or longer, or both—were used to assess predictive validity both overall and across deciles of baseline risk as determined by age, sex, and comorbidity. For infected patients both inside and outside of the



### The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Mervyn Singer, MD, FRCP; Clifford S. Deutschman, MD, MS; Christopher Warren Seymour, MD, MSc; Manu Shankar-Hari, MSc, MD, FFICM; Djillali Annane, MD, PhD; Michael Bauer, MD; Rinaldo Bellomo, MD; Gordon R. Bernard, MD; Jean-Daniel Chiche, MD, PhD; Craig M. Coopersmith, MD; Richard S. Hotchkiss, MD; Mitchell M. Levy, MD; John C. Marshall, MD; Greg S. Martin, MD, MSc; Steven M. Opal, MD; Gordon D. Rubenfeld, MD, MS; Tom van der Poll, MD, PhD; Jean-Louis Vincent, MD, PhD; Derek C. Angus, MD, MPH

Table 2. Terminology and International Classification of Diseases Coding

JAMA, 2016;315(8):801-810, doi:10.1001/jama,2016.0287




Table 2. Terriminelegy and international classification of Discusses County					
Current Guidelines and Terminology	Sepsis	Septic Shock			
1991 and 2001 consensus terminology <sup>9,10</sup>	Severe sepsis Sepsis-induced hypoperfusion	Septic shock <sup>13</sup>			
2015 Definition	Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection	Septic shock is a subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially			
		increase mortality			
2015 Clinical criteria	Suspected or documented infection and an acute increase of ≥2 SOFA points (a proxy for organ dysfunction)	Sepsis <sup>a</sup> and vasopressor therapy needed to elevate MAP ≥65 mm Hg and lactate >2 mmol/L (18 mg/dL) despite adequate fluid resuscitation <sup>13</sup>			
Recommended primary ICD codes <sup>a</sup>					
ICD-9	995.92	785.52 Org			
ICD-10 <sup>a</sup>	R65.20	R65.21			
Framework for implementation for coding and specified period <sup>b</sup>					

Within specified period around suspect

1. Identify sepsis by using a clinical critilite-threatening organ dysfunction

2. Assess for shock criteria, using admi vasopressors, MAP <65 mm Hg, and lac

 $(18 \text{ mg/dL})^d$ 

research

Organ dysfunction in focus:
-fluid/vasopressor
-lactate
-MAP



#### The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Mervyn Singer, MD, FRCP; Clifford S. Deutschman, MD, MS; Christopher Warren Seymour, MD, MSc; Manu Shankar-Hari, MSc, MD, FFICM; Djillali Annane, MD, PhD; Michael Bauer, MD; Rinaldo Bellomo, MD; Gordon R. Bernard, MD; Jean-Daniel Chiche, MD, PhD; Craig M. Coopersmith, MD; Richard S. Hotchkiss, MD; Mitchell M. Levy, MD; John C. Marshall, MD; Greg S. Martin, MD, MSc; Steven M. Opal, MD; Gordon D. Rubenfeld, MD, MS; Tom van der Poll, MD, PhD; Jean-Louis Vincent, MD, PhD; Derek C. Angus, MD, MPH



#### Screening for Patients Likely to Have Sepsis

A parsimonious clinical model developed with multivariable logistic regression identified that any 2 of 3 clinical variables— Glasgow Coma Scale score of 13 or less, systolic blood pressure of 100 mm Hg or less, and respiratory rate 22/min or greater—offered predictive validity (AUROC = 0.81; 95% CI, 0.80-0.82) similar to that of the full SOFA score outside the ICU. 12 This model was robust to multiple sensitivity analyses including a more simple assessment of altered mentation (Glasgow Coma Scale score <15) and in the out-of-hospital, emergency department, and ward settings within the external US and non-US data sets.

For patients with suspected infection within the ICU, the SOFA score had predictive validity (AUROC = 0.74; 95% CI, 0.73-0.76) superior to that of this model (AUROC = 0.66; 95% CI, 0.64-0.68), likely reflecting the modifying effects of interventions (eg, vasopressors, sedative agents, mechanical ventilation). Addition of lactate measurement did not meaningfully improve predictive validity but may help identify patients at intermediate risk.

#### Box 4. qSOFA (Quick SOFA) Criteria

JAMA. 2016;315(8):801-810. doi:10.1001/jama.2016.0287

Respiratory rate ≥22/min

Altered mentation

Systolic blood pressure ≤100 mm Hg




Yes

Septic shock

#### Special Communication | CARING FOR THE CRITICALLY ILL PATIENT

### The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)





Bilirubin
Platelet count



### The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Mervyn Singer, MD, FRCP; Clifford S. Deutschman, MD, MS; Christopher Warren Seymour, MD, MSc; Manu Shankar-Hari, MSc, MD, FFICM; Djillali Annane, MD, PhD; Michael Bauer, MD; Rinaldo Bellomo, MD; Gordon R. Bernard, MD; Jean-Daniel Chiche, MD, PhD; Craig M. Coopersmith, MD; Richard S. Hotchkiss, MD; Mitchell M. Levy, MD; John C. Marshall, MD; Greg S. Martin, MD, MSc; Steven M. Opal, MD; Gordon D. Rubenfeld, MD, MS; Tom van der Poll, MD, PhD; Jean-Louis Vincent, MD, PhD; Derek C. Angus, MD, MPH


JAMA, 2016;315(8):801-810. doi:10.1001/jama,2016,0287

#### Conclusions

These updated definitions and clinical criteria should clarify longused descriptors and facilitate earlier recognition and more timely management of patients with sepsis or at risk of developing it. This process, however, remains a work in progress. As is done with software and other coding updates, the task force recommends that the new definition be designated Sepsis-3, with the 1991 and 2001 iterations being recognized as Sepsis-1 and Sepsis-2, respectively, to emphasize the need for future iterations.



### My problem remains unsolved...





## Pathomechanism of critical illness – New insight




### Health=balance between the antagonistic forces





### Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy

Richard S. Hotchkiss<sup>1</sup>, Guillaume Monneret<sup>2</sup> and Didier Payen<sup>3</sup>





# Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy

Richard S. Hotchkiss<sup>1</sup>, Guillaume Monneret<sup>2</sup> and Didier Payen<sup>3</sup>

Nature Reviews | Immunology Volume 13 | December 2013 | 862-874

Pro-

# More on that tomorrow at 10:30 – Sepsis & Love

Antiinflammation immunosuppression and recurrent infections



Goood! ©

#### Special Communication | CARING FOR THE CRITICALLY ILL PATIENT


### The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Mervyn Singer, MD, FRCP; Clifford S. Deutschman, MD, MS; Christopher Warren Seymour, MD, MSc; Manu Shankar-Hari, MSc, MD, FFICM; Djillali Annane, MD, PhD; Michael Bauer, MD; Rinaldo Bellomo, MD; Gordon R. Bernard, MD; Jean-Daniel Chiche, MD, PhD; Craig M. Coopersmith, MD; Richard S. Hotchkiss, MD; Mitchell M. Levy, MD; John C. Marshall, MD; Greg S. Martin, MD, MSc; Steven M. Opal, MD; Gordon D. Rubenfeld, MD, MS; Tom van der Poll, MD, PhD; Jean-Louis Vincent, MD, PhD; Derek C. Angus, MD, MPH

#### Table 2. Terminology and International Classification of Diseases Coding

Current Guidelines and Terminology	Sepsis	Septic Shock
1991 and 2001 consensus terminology <sup>9,10</sup>	Severe sepsis Sepsis-induced hypoperfusion	Septic shock <sup>13</sup>
2015 Definition	Sepsis is life-threatening organ	Septic shock is a subset of sepsis in which underlying
	dysfunction caused by a dysregulated host response to infection	circulatory and cellular/metabolic abnormalities are profound enough to substantially
2015 Clinical criteria	Suspected or documented infection and an acute increase of ≥2 SOFA points (a proxy for organ dysfunction)	increase mortality  Sepsis <sup>a</sup> and vasopressor therapy needed to elevate MAP ≥65 mm Hg and lactate >2 mmol/L (18 mg/dL) despite adequate fluid resuscitation <sup>13</sup>
Recommended primary <i>ICD</i> codes <sup>a</sup>		
ICD-9	995.92	785.52
ICD-10 <sup>a</sup>	R65.20	R65.21
Framework for implementation for coding and research	Identify suspected infection by using concomitant orders for blood cultures and antibiotics (oral or parenteral) in a specified period within specified period around suspected infection <sup>c</sup> :  1. Identify sepsis by using a clinical criterion for life-threatening organ dysfunction  2. Assess for shock criteria, using administration of vasopressors, MAP <65 mm Hg, and lactate >2 mmol/L	

 $(18 \text{ mg/dL})^d$ 





New guidelines: SSC-2016



#### **CONFERENCE REPORTS AND EXPERT PANEL**



#### Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

Andrew Rhodes<sup>1\*</sup>, Laura E. Evans<sup>2</sup>, Waleed Alhazzani<sup>3</sup>, Mitchell M. Levy<sup>4</sup>, Massimo Antonelli<sup>5</sup>, Ricard Fe

21 aspects

**Results:** The Surviving Sepsis Guideline panel provided 93 statements on early management and resuscitude patients with sepsis or septic shock. Overall, 32 were strong recommendations, 39 were weak recommendation was provided for four questions.

"Sepsis specific"

#### D. ANTIMICROBIAL THERAPY

- We recommend that administration of IV antimicrobials should be initiated as soon as possible after recognition and within one hour for both sepsis and septic shock (strong recommendation, moderate quality of evidence).
- We recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis
  or septic shock to cover all likely pathogens (including bacterial and potentially fungal or viral coverage) (strong
  recommendation, moderate quality of evidence).

#### L. ANTICOAGULANTS

 We recommend against the use of antithrombin for the treatment of sepsis and septic shock (strong recommendation, moderate quality of evidence).

### The rest: Good Medicine




### Novel treatments (?)



Is this patient septic or not?



### I have never treated "SEPSIS" in my life! But...



You don't treat SEPSIS but: Organ dysfunction +/- infection

Etc, etc, etc....

dysfunction



### Does the patient have infection or not?

Infection = ABs

No infection = No ABs



### Signs of infection

Clinical signs:

Most important

Not good enough

• Fever (>38°C), WBC (>12 000):

• Low sensitivity (~50%)

Galicier L and Richet H. Infect Control Hosp

Microbiology:

• Results: 24 hours or more

Poooor!

Very late!



### We need biomarkers!

Pierrakos and Vincent Critical Care 2010, 14:R15 http://ccforum.com/content/14/1/R15



# More on that: 17:15-18:15






#### Sepsis – from pathophysiology to individualized patient care

care

Ildikó László MD1, Domonkos Trásy MD1, Zsolt Molnár MD PhD1, János Fazakas MD PhD2

Journal of Immunology Research, 2015; Volume 2015, ID 510436, 13 pages http://dx.doi.org/10.1155/2015/510436









### Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy


Richard S. Hotchkiss<sup>1</sup>, Guillaume Monneret<sup>2</sup> and Didier Payen<sup>3</sup>





### Rationale – "Regaining Balance"






Kellum JA et al., (GenIMS Study); Arch Intern Med 2007; 167:1655-63



### Cytokine adsorbtion...



...and not only in septic patients: all with Cytokine Storm



### What is it?






Biocompatible, porous polymer polystyrene beads




### How does it work?



- •300ml cartridge with "Bead" design
- •120ml blood volume / filling volume
- •Pre-filled with 0.9% sodium chloride
- •Gamma-sterilized, storable for 3 years
- al avy flavy resistance




### How to apply? – on RRT





### How to apply? – on RRT






### CRRT+ECMO+CytoSorb





### How to apply? – on its own





### At the moment: experimental data

Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis

Peng ZY, Wang HZ, Carter MJ, Dileo MV, Bishop JV, Zhou FH, Wen XY, Rimmelé T, Singbartl K, Federspiel WJ, Clermont G, Kellum JA

Kid Hemoadsorption Reprograms Inflammation in Experimental Gram-Negative

Sentic Peritonitis: Insights from In Vivo and In Silico Studies

Attenuates inflammatory response of leukocytes Eliminates inflammatory cytokines

Keeps infection localised

Improves hemodynamics

Peng ZY, Bishop JV, Wen XY, Elder MM, Zhou F, Chuasuwan A, Carter MJ, Devlin JE, Kaynar AM, Singbartl K, Pike F, Parker RS, Clermont G, Federspiel WJ, Kellum JA.

Crit Care. 2014 Jul 3;18(4):R141



### At the moment: case reports

Case Rep

Cytosorb™ in a Patient with *Legionella*-Pneumonia Associated **Rhabdomyolysis: A Case Report** 

Proved to be safe

Atenuated inflammatory response (PCT, IL-6) Improved organ function

Survival

combination of ECNAO First succa

Romanian Journal of Anaesthesia and Intensive Care 2014 Vol 21 No 2, 134-138

removal t Effects of a novel cytokine haemoadsorbtion system on report inflammatory response in septic shock after cephalic pancreatectomy – a case report

Frank Bruenger<sup>1</sup>, Luka

Dana Tomescu<sup>1,4</sup>, Simona O. Dima<sup>2</sup>, Sabina Tănăsescu<sup>1</sup>, Cristiana Pistol Tănase<sup>3</sup>, Anca Năstase<sup>2</sup>, Mihai Popescu<sup>4</sup>



### Registry: 15 countries so far



Thank you very much for

your support and

registry!

cooperation for this

Registry data base

The registry data base is set up with the system OpenClinica. To get an impression of how this system works, please visit our registry homepage where you can find a test data base. In the LogIn area you can get a test access.

For further information on the use of the data base please refer to the attached working instruction.

On the next page you'll find the results of our first intermediate analysis.

Please continue to support us in extending the data collection on the use of the CytoSorb-Adsorber so that our results are built on a broader basis in the future.

Homepage:

http://www.cytosorb-registry.org/

interested sites:

Study team Jena University Hospital Center for Clinical Studies



Prof. Dr. Frank M. Brunkhorst



Manja Schein



14 trials registered on ClinicalTrials.gov!







### Attenuating the cytokine storm early?

ClinicalTrials.gov		Example: "Heart attack" AND "Los Angeles"
Cunicui Frais.gov	Search for studies:	
A service of the U.S. National Institutes of Health	Search	
		Advanced Search   Help   Studies by Topic   Glossan

## The ACESS trial

Adsorbtion of Cytokines Early in Septic Shock

Locations)			NCT02288975		
Verified November 201	4 by Szeged Uni	versity		First received: November 5, 2014	
Sponsor: Domonkos Trásy			Last updated: November 14, 2014 Last verified: November 2014 History of Changes		
<mark>Information provided</mark> Domonkos Trásy, Sze				Section of Conference # 400	
Full Text View	Tabular View	No Study Results Posted	Disclaimer	How to Read a Study Record	



### ACESS - Inclusion criteria

- Suspected sepsis of medical etiology
- IPPV
- PCT > 3 ng/ml
- Norepinephrine  $\geq 10 \mu g/min$
- PiCCO confirmed normovolemia and CO
- Signs of hypoperfusion: ScvO<sub>2</sub>, lactate, dCO<sub>2</sub>,

8 patients over 6 months!



mmHg

400

350

300

250

200 -

150 -

100 -

T0


T12

Cytosorb [median; 25-75th IQR]

T24

PaO, / FiO,

### ACESS – preliminary results (6pts)






## Final thoughts on sepsis



### Thinking has no alternative!



Auguste Rodin: The Thinker (1880)









YouTube: oncall@jate